Abstract:Objective For major depressive disorder (MDD), there has been a lack of neuroimaging markers of efficacy of pharmacological treatment. In this study, we aimed to explore the neuroimaging mechanisms in patients with first-episode MDD and identify markers that predict the efficacy of 5-hydroxytryptamine reuptake inhibitors (SSRIs) with the use of resting-state brain imaging technology. Methods A total of 101 patients with first-episode MDD and 53 normal controls were finally included in this study. Based on the reduction rate of the score of Hamilton Depression Rating Scale (HAMD-17) during the 2-week SSRI treatment, 31 patients were assigned into the unresponsive group and 32 were assigned into the responsive group. The brain function was compared between patients with MDD and normal controls, and the diagnostic value of brain function was analyzed. With brain regions showing differences between patients with MDD and normal controls as a mask, and the brain function between the responsive and unresponsive groups were compared. Correlations between brain function the HAMD-17 score reduction rate during the 2-week SSRI treatment were analyzed. Results Compared to normal controls, patients with MDD showed increased ReHo in the left parahippocampal gyrus and right parahippocampal gyrus, decreased ReHo in the right middle occipital gyrus, and decreased functional connectivity between the right and left parahippocampal gyri, right middle occipital gyrus and middle temporal gyrus. Receiver operator characteristic (ROC) curve analysis showed that the area under the curve (AUC) was 0.544 (95% CI: 0.445–0.644) for ReHo and 0.822 (95% CI: 0.734–0.909) for functional connectivity. Logistic regression pooling of the differences in ReHo mean time series with the functional connectivity mean time series was performed for the ROC curve analysis, which showed an AUC of 0.832 (95% CI: 0.752–0.911). Compared to the responsive group, the unresponsive group showed elevated ReHo in the right parahippocampal gyrus and lower functional connectivity in the middle temporal gyrus. We also found that the ReHo value was negatively correlated with the HAMD-17 score reduction after 2 weeks of SSRI treatment. Conclusion Altered resting-state brain function in some regions might be a neurobiological marker for the diagnosis of MDD, and ReHo values are expected to be predictors of patient response to treatment with SSRIs. Clinical Trial Registration [ http://www.chictr.org.cn/ ], identifier [ChiCTR1900028722].

Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment

Frequency-Specific Changes in the Fractional Amplitude of the Low-Frequency Fluctuations in the Default Mode Network in Medication-Free Patients with Bipolar II Depression: A Longitudinal Functional MRI Study

The relationship between frontal alpha asymmetry and self-report measurements of depression, anxiety, stress, and self-regulation

Emotion-induced frontal α asymmetry as a candidate predictor of relapse after discontinuation of antidepressant medication

Frontal alpha asymmetry is associated with chronic stress and depression, but not with somatoform disorders

EEG measures of brain arousal in relation to symptom improvement in patients with major depressive disorder: Results from a randomized placebo-controlled clinical trial

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Regional White Matter Integrity Predicts Treatment Response to Escitalopram and Memantine in Geriatric Depression: A Pilot Study

Frontal alpha EEG asymmetry before and after behavioral activation treatment for depression

Frontal Theta Asymmetry may be a new target for reducing the severity of depression and improving cognitive function in depressed patients

Mapping the effect of escitalopram treatment on amplitude of low-frequency fluctuations in patients with depression: a resting-state fMRI study

One size does not fit all: notable individual variation in brain activity correlates of antidepressant treatment response

Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study

Frontal alpha asymmetry during emotion regulation in adults with lifetime major depression

An Electroencephalographic Signature Predicts Antidepressant Response in Major Depression

Normalization of EEG in depression after antidepressant treatment with sertraline? A preliminary report

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Contribution of resting-state functional connectivity of the subgenual anterior cingulate to prediction of antidepressant efficacy in patients with major depressive disorder

Heart rate variability as a biomarker of anxious depression response to antidepressant medication

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder